Benzinga | Jun 16, 2021 08:17AM EDT

Stifel Maintains Buy on Sage Therapeutics, Lowers Price Target to $95

Stifel analyst Paul Matteis maintains Sage Therapeutics (NASDAQ:SAGE) with a Buy and lowers the price target from $121 to $95.Stifel analyst Paul Matteis maintains Sage Therapeutics (NASDAQ:SAGE) with a Buy and lowers the price target from $121 to $95.